ITL Health Group

ITL Health Group

ITL Health Group is a pioneering medical technology company, supplier and strategic partner with a global reach. The company operates through two divisions, ITL BioMedical and MyHealthTest, and is publicly listed on the Australian Stock Exchange (ASX: ITD). With a rich IP portfolio of over 50 patents, the company sets industry benchmarks in product innovation and market intelligence to ensure safety, efficiency, and compliance. Serving healthcare markets in over 55 countries across North America, South America, Europe, Asia, the Middle East, and Australia, ITL Health Group caters to blood banks, hospitals, health systems, laboratories, and veterinary facilities.

ITL Health Group has positioned itself as a leading provider of niche ancillary products for the blood culture testing market, which is projected to grow from US$3.3 billion in 2016 to US$4.8 billion by 2021 according to MarketsandMarkets. Under the ITL BioMedical division, the company excels in designing and manufacturing pioneering biological sampling systems for human and animal use, as well as medical and surgical products for healthcare settings. Notable brands under ITL BioMedical include ITL Clinical and SampLok.

As a wholly owned subsidiary of ITL Health Group, MyHealthTest is at the forefront of a new era in pathology testing. The company allows consumers to conveniently order tests and take samples in the comfort and privacy of their own homes. The samples are then processed by a fully accredited laboratory to ensure accuracy and reliability. As of January 2018, MyHealthTest offers tests including the HbA1c diabetes test and the Thyroid TSH test, with plans to launch Cholesterol and Prostate tests in the near future.

For further information, visit www.itlhealthgroup.com.

Overall, ITL Health Group has established itself as an influential player in the global medical technology sphere, with a strong focus on innovation, quality, and expanding its market footprint. As a publicly listed company, it offers potential investors an opportunity to delve into the rapidly evolving healthcare sector, particularly as it continues to address the evolving demands and challenges of the industry worldwide.